HAPLN1基质因子:与多发性骨髓瘤患者不良结局相关的骨髓归巢因子
骨髓微环境对多发性骨髓瘤(MM)细胞的播散、生长和存活至关重要,但基质因子(matrikine)的作用尚不清楚。本研究发现源自透明质酸和蛋白聚糖连接蛋白1(HAPLN1)的基质因子可诱导MM细胞黏附于纤连蛋白、内皮细胞和基质细胞,并促进趋化和趋动迁移;在小鼠异种移植模型中,MM细胞优先归巢至经HAPLN1基质因子预处理的骨髓。机制上,HAPLN1基质因子通过NF-κB诱导IFN-β,进而激活STAT1,后者是黏附、迁移及骨髓归巢所必需的。骨髓样本中HAPLN1水平较高与新诊断MM患者无进展生存期较差相关。
要点
- HAPLN1基质因子诱导MM细胞黏附于骨髓基质成分并促进趋化迁移。
- 小鼠异种移植模型中MM细胞优先归巢至HAPLN1基质因子处理的骨髓。
- HAPLN1通过NF-κB-IFN-β-STAT1信号轴促进MM细胞骨髓归巢。
核心结论
- 骨髓微环境中存在的HAPLN1基质因子作为趋化因子,通过NF-κB-IFN-β-STAT1信号通路在MM细胞骨髓归巢中起重要作用,并可能有助于识别预后不良的患者。
- 本研究为靶向HAPLN1基质因子治疗MM提供了机制依据。
研究设计与样本
- 体外实验、小鼠异种移植模型及患者骨髓样本分析。
- 原文未报告样本量。
主要发现
- HAPLN1基质因子诱导MM细胞黏附于纤连蛋白、内皮细胞和基质细胞,并诱导趋化和趋动迁移。
- 小鼠异种移植模型中,MM细胞优先归巢至HAPLN1基质因子预处理的骨髓。
- STAT1被HAPLN1基质因子激活,且是诱导MM细胞黏附、迁移、迁移相关基因及骨髓归巢所必需。
- STAT1激活由IFN-β介导,IFN-β在HAPLN1基质因子刺激后由NF-κB诱导产生。
- 骨髓样本中HAPLN1水平较高与新诊断MM患者无进展生存期较差相关。
关键数值与推荐
- 原文未报告具体数值、阈值或推荐等级。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The bone marrow (BM) microenvironment is critical for dissemination, growth, and survival of multiple myeloma (MM) cells. Homing of myeloma cells to the BM niche is a crucial step in MM dissemination, but the mechanisms involved are incompletely understood. In particular, any role of matrikines, neofunctional peptides derived from extracellular matrix proteins, remains unknown. Here, we report that a matrikine derived from hyaluronan and proteoglycan link protein 1 (HAPLN1) induces MM cell adhesion to the BM stromal components, such as fibronectin, endothelial cells, and stromal cells and, furthermore, induces their chemotactic and chemokinetic migration. In a mouse xenograft model, we show that MM cells preferentially home to HAPLN1 matrikine-conditioned BM. The transcription factor STAT1 is activated by HAPLN1 matrikine and is necessary to induce MM cell adhesion, migration, migration-related genes, and BM homing. STAT1 activation is mediated by interferon beta (IFN-β), which is induced by NF-κB after stimulation by HAPLN1 matrikine. Finally, we also provide evidence that higher levels of HAPLN1 in BM samples correlate with poorer progression-free survival of patients with newly diagnosed MM. These data reveal that a matrikine present in the BM microenvironment acts as a chemoattractant, plays an important role in BM homing of MM cells via NF-κB-IFN-β-STAT1 signaling, and may help identify patients with poor outcomes. This study also provides a mechanistic rationale for targeting HAPLN1 matrikine in MM therapy.
引用
- Chang HY, Huynh M, Roopra A, et al. HAPLN1 matrikine: a bone marrow homing factor linked to poor outcomes in patients with MM. Blood Adv. 2023. PMID: 37647592. doi:10.1182/bloodadvances.2023010139
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。